DBV Technologies (DBV) Corporate presentation summary

Mission and company overview

• Focused on developing novel treatments for pediatric food allergy, especially peanut allergy, using epicutaneous immunotherapy (EPIT) via the VIASKIN patch technology.

• Over 1.1 million patches administered to more than 1,600 children aged 1-7 years.

• Science-driven leadership with deep regulatory and commercial experience.

Product pipeline and clinical milestones

• VIASKIN Peanut patch is the lead product, targeting children aged 1-3 and 4-7 years.

• VITESSE Phase 3 study in 4-7 year-olds met primary endpoint; BLA submission anticipated in 1H 2026, eligible for priority review.

• EPITOPE Phase 3 study in 1-3 year-olds met primary endpoint; BLA submission anticipated in 2H 2026 under Accelerated Approval pathway.

• EMA guidance supports MAA submission for 1-7 year-olds in Europe, requiring three studies including new safety data.

Market opportunity and dynamics

• Approximately 670,000 children aged 1-7 in the US and 615,000 in the EU have peanut allergy.

• Annual economic impact of peanut allergy in the US is $33B, with significant quality of life burden.

• Current treatments (oral immunotherapy, omalizumab) have limitations; 90% of allergists see need for new options.

• VIASKIN Peanut patch offers at-home, non-invasive, daily application with no oral ingestion or injections.